Skip to main content
. Author manuscript; available in PMC: 2019 Jan 4.
Published in final edited form as: Cell Rep. 2018 Nov 13;25(7):1982–1993.e4. doi: 10.1016/j.celrep.2018.10.062

Figure 5. Rapid In Vivo Protection with DMAb-11.

Figure 5.

(A) Overview of the injection regimens. DMAbs were administered on day −14 or day −8 before lethal challenge with 1,000LD50 of ma-EBOV (n = 10 mice/group). Animals were monitored for 22 days post-challenge for signs of disease and weight loss.

(B and C) Survival (B) and percent weight change (C) in DMAb-11 groups receiving injection on day −14 or day −8 and the negative control. ***p < 0.001.